Cergutuzumab amunaleukin

N/A

Report date: 2024/12/16 20:00:57

Base Information

Drug NameCergutuzumab amunaleukin

Drug Alias NameCEA-IL2V,CEA-IL-2VRG-7813RO-6895882

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibodyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionCarcinoembryonic antigen related cell adhesion molecule 5 antagonistsInterleukin-2 receptor agonists

TargetsCarcinoembryonic antigen related cell adhesion molecule 5Interleukin-2 receptor

Therapy Area/IndicationsSolid tumoursNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryCanadaUnited StatesNetherlands +[9]

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesF. Hoffmann-La Roche Ltd

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesF. Hoffmann-La Roche Ltd

Active IndicationsN/A

Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A